(S)-N-(1-hydroxy-3-phenylpropan-2-yl)-4-(pyridin-4-yl)benzamide | 1127307-68-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (S)-N-(1-hydroxy-3-phenylpropan-2-yl)-4-(pyridin-4-yl)benzamide
• 英文别名: N-[(1S)-1-benzyl-2-hydroxyethyl]-4-pyridin-4-ylbenzamide；N-[(2S)-1-hydroxy-3-phenylpropan-2-yl]-4-pyridin-4-ylbenzamide
• CAS: 1127307-68-9
• 化学式: C₂₁H₂₀N₂O₂
• 分子量: 332.402
• InChiKey: YVKVSKQNYIHXPX-FQEVSTJZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  62.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  L-苯丙氨醇 、 4-吡啶-4-基苯甲酸 在 1-羟基苯并三唑 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 0.17h， 以21%的产率得到(S)-N-(1-hydroxy-3-phenylpropan-2-yl)-4-(pyridin-4-yl)benzamide
  参考文献：
  名称：

  基于结构的药物设计鉴定选择性双重ROCK1和ROCK2抑制剂

  摘要：

  一项HTS运动确定了化合物1，这是一种出色的命中分子，可启动药物化学工作以优化ROCK1和ROCK2双重抑制剂。取代吡啶铰链结合基序的（2-Cl，2-NH 2，2 -F，3-F）或用嘧啶替代，提供了具有干净CYP抑制谱的化合物。在PKA，ROCK1和ROCK2中获得了早期铅化合物的共晶体结构。这为药物化学驱动化合物设计提供了关键的结构信息。结构数据表明，中心苄基碳原子的优选构型为（R），并且将该信息应用于化合物设计可得到化合物16。该化合物在酶和细胞分析中均显示为有效且选择性的双重ROCK抑制剂，口服给药后在视网膜神经纤维层模型中有效。该工具化合物可通过AbbVie Compound Toolbox获得。最后，共晶结构还确定了ROCK2中的天冬氨酸残基176和218（它们是PKA中的谷氨酸）可以作为残基来靶向，以同时驱动效价和激酶组选择性。在化合物系列中引入哌啶-3-氨基甲胺基团产生了化合

  DOI：

  10.1021/acs.jmedchem.8b01098

文献信息

• [EN] 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS<br/>[FR] COMPOSÉS 4-(4-PYRIMIDYL)-BENZAMIDES ET UTILISATION DE CEUX-CI COMME MODULATEURS DE L'ACTIVITÉ DE KINASES RHO (ROCK)
  申请人：ABBOTT GMBH & CO KG

  公开号：WO2009027392A1

  公开（公告）日：2009-03-05

  The present invention relates to novel 4-(4-pyridyl)-benzamides of the formula (I). The compounds I possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of Rho kinases (ROCKs). R1 and R2 are, independently of each other, hydrogen, hydroxy, cyano, C1-C8-alkyl, C1- C8-haloalkyl, C1-C8-alkoxy or C1-C8-haloalkoxy; R3, R4, R5 and R6 are, independently of each other, hydrogen, hydroxy, halogen, cyano, C1-C8-alkyl, C1-C8-haloalkyl, C1-C8-alkoxy, C1-C8-haloalkoxy, amino, C1-C8-alkylamino or di-(C1-C8-alkyl)-amino; R7 is hydrogen, C1-C8-alkyl, C1-C8-haloalkyl, aryl or aryl-C1-C8-alkyl; R8 is a group of the formula -X-W, where X is a single bond, C1-C4-alkylene or C1-C4-alkylene-O-, where the alkylene group in the three last-mentioned radicals may be linear or branched and may be partly or fully halogenated and/or may be substituted by a hydroxyl group and/or may be interrupted by an oxygen atom; and W is a cyclic radical selected from phenyl and a 5- or 6-membered saturated, partly unsaturated or aromatic heterocyclic ring which contains as ring members 1, 2 or 3 heteroatoms selected from O, S and N and optionally 1 or 2 carbonyl groups; R9 is a group of the formula -Y-Z, where Z is hydrogen, halogen, OR11, NR12R13, S(O)m-R14, phenyl which may carry 1, 2, 3 or 4 substituents R15 or a 5- or 6-membered saturated, partly unsaturated or aromatic heterocyclic ring; and Y is linear or branched C1C4-alkylene which may be partly or fully halogenated and/or may be substituted by a hydroxyl group and/or a phenyl ring; or, in case Z is phenyl or the 5- or 6-membered heterocyclic ring as defined above, Y can also be a single bond.

  本发明涉及公式（I）的新型4-(4-吡啶基)-苯甲酰胺。化合物I具有有价值的治疗性能，并且特别适用于治疗对Rho激酶（ROCKs）调节产生反应的疾病。R1和R2分别为氢、羟基、氰基、C1-C8-烷基、C1-C8-卤代烷基、C1-C8-烷氧基或C1-C8-卤代烷氧基；R3、R4、R5和R6分别为氢、羟基、卤素、氰基、C1-C8-烷基、C1-C8-卤代烷基、C1-C8-烷氧基、C1-C8-卤代烷氧基、氨基、C1-C8-烷基氨基或二(C1-C8-烷基)-氨基；R7为氢、C1-C8-烷基、C1-C8-卤代烷基、芳基或芳基-C1-C8-烷基；R8为-X-W的基团，其中X为单键、C1-C4-烷基或C1-C4-烷基-O-，在上述最后三个基团中的烷基可以是直链或支链，可以部分或完全卤代，和/或可以被羟基取代，和/或可以被氧原子打断；W为选择自苯基和含有1、2或3个来自O、S和N的杂原子以及可选地包含1或2个羰基的5-或6-成员饱和、部分不饱和或芳香杂环的环基；R9为-Y-Z的基团，其中Z为氢、卤素、OR11、NR12R13、S(O)m-R14、可能携带1、2、3或4个取代基R15的苯基或5-或6-成员饱和、部分不饱和或芳香杂环的环基；Y为线性或支链的C1-C4-烷基，可以部分或完全卤代，和/或可以被羟基取代，和/或可以是苯环；或者，如果Z为苯基或上述定义的5-或6-成员杂环环，Y也可以是单键。
• 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS
  申请人：Mack Helmut

  公开号：US20100273828A1

  公开（公告）日：2010-10-28

  The present invention relates to novel 4-(4-pyridyl)-benzamides of the formula (I). The compounds I possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of Rho kinases (ROCKs). R 1 and R 2 are, independently of each other, hydrogen, hydroxy, cyano, C 1 -C 8 -alkyl, C 1 -C 8 -haloalkyl, C 1 -C 8 -alkoxy or C 1 -C 8 -haloalkoxy; R 3 , R 4 , R 5 and R 6 are, independently of each other, hydrogen, hydroxy, halogen, cyano, C 1 -C 8 -alkyl, C 1 -C 8 -haloalkyl, C 1 -C 8 -alkoxy, C 1 -C 8 -haloalkoxy, amino, C 1 -C 8 -alkylamino or di-(C 1 -C 8 -alkyl)-amino; R 7 is hydrogen, C 1 -C 8 -alkyl, C 1 -C 8 -haloalkyl, aryl or aryl-C 1 -C 8 -alkyl; R 8 is a group of the formula —X—W, where X is a single bond, C 1 -C 4 -alkylene or C 1 -C 4 -alkylene-O—, where the alkylene group in the three last-mentioned radicals may be linear or branched and may be partly or fully halogenated and/or may be substituted by a hydroxyl group and/or may be interrupted by an oxygen atom; and W is a cyclic radical selected from phenyl and a 5- or 6-membered saturated, partly unsaturated or aromatic heterocyclic ring which contains as ring members 1, 2 or 3 heteroatoms selected from O, S and N and optionally 1 or 2 carbonyl groups; R 9 is a group of the formula —Y—Z, where Z is hydrogen, halogen, OR 11 , NR 12 R 13 , S(O) m —R 14 , phenyl which may carry 1, 2, 3 or 4 substituents R 15 or a 5- or 6-membered saturated, partly unsaturated or aromatic heterocyclic ring; and Y is linear or branched C 1 C 4 -alkylene which may be partly or fully halogenated and/or may be substituted by a hydroxyl group and/or a phenyl ring; or, in case Z is phenyl or the 5- or 6-membered heterocyclic ring as defined above, Y can also be a single bond.

  本发明涉及式(I)的新型4-(4-吡啶基)-苯甲酰胺化合物。化合物I具有有价值的治疗性能，特别适用于治疗对Rho激酶（ROCKs）调节有反应的疾病。其中，R1和R2分别独立地为氢、羟基、氰基、C1-C8烷基、C1-C8卤代烷基、C1-C8烷氧基或C1-C8卤代烷氧基；R3、R4、R5和R6分别独立地为氢、羟基、卤素、氰基、C1-C8烷基、C1-C8卤代烷基、C1-C8烷氧基、C1-C8卤代烷氧基、氨基、C1-C8烷基氨基或二-(C1-C8烷基)-氨基；R7为氢、C1-C8烷基、C1-C8卤代烷基、芳基或芳基-C1-C8烷基；R8为公式-X-W的基团，其中X为单键、C1-C4-烷基或C1-C4-烷基-O-，其中上述三种基团中的烷基基团可以是直链或支链并且可以部分或完全卤代和/或可以被羟基取代和/或可以被氧原子中断；W为从苯基和一个含有1、2或3个从O、S和N中选择的杂原子和可选地1或2个羰基的5-或6-成员饱和、部分不饱和或芳香杂环环中选择的环状基团；R9为公式-Y-Z的基团，其中Z为氢、卤素、OR11、NR12R13、S(O)m-R14、可以携带1、2、3或4个取代基R15的苯基或5-或6-成员饱和、部分不饱和或芳香杂环环；Y为线性或支链的C1-C4-烷基，可以部分或完全卤代和/或可以被羟基和/或苯环取代；或者，如果Z为上述定义的苯基或5-或6-成员杂环环，则Y也可以是单键。
• 4-(4-pyridinyl)-benzamides and their use as rock activity modulators
  申请人：AbbVie Deutschland GmbH & Co KG

  公开号：US08895749B2

  公开（公告）日：2014-11-25

  The present invention relates to novel 4-(4-pyridyl)-benzamides of the formula (I). The compounds I possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of Rho kinases (ROCKs). R1 and R2 are, independently of each other, hydrogen, hydroxy, cyano, C1-C8-alkyl, C1-C8-haloalkyl, C1-C8-alkoxy or C1-C8-haloalkoxy; R3, R4, R5 and R6 are, independently of each other, hydrogen, hydroxy, halogen, cyano, C1-C8-alkyl, C1-C8-haloalkyl, C1-C8-alkoxy, C1-C8-haloalkoxy, amino, C1-C8-alkylamino or di-(C1-C8-alkyl)-amino; R7 is hydrogen, C1-C8-alkyl, C1-C8-haloalkyl, aryl or aryl-C1-C8-alkyl; R8 is a group of the formula —X—W, where X is a single bond, C1-C4-alkylene or C1-C4-alkylene-O—, where the alkylene group in the three last-mentioned radicals may be linear or branched and may be partly or fully halogenated and/or may be substituted by a hydroxyl group and/or may be interrupted by an oxygen atom; and W is a cyclic radical selected from phenyl and a 5- or 6-membered saturated, partly unsaturated or aromatic heterocyclic ring which contains as ring members 1, 2 or 3 heteroatoms selected from O, S and N and optionally 1 or 2 carbonyl groups; R9 is a group of the formula —Y—Z, where Z is hydrogen, halogen, OR11, NR12R13, S(O)m—R14, phenyl which may carry 1, 2, 3 or 4 substituents R15 or a 5- or 6-membered saturated, partly unsaturated or aromatic heterocyclic ring; and Y is linear or branched C1C4-alkylene which may be partly or fully halogenated and/or may be substituted by a hydroxyl group and/or a phenyl ring; or, in case Z is phenyl or the 5- or 6-membered heterocyclic ring as defined above, Y can also be a single bond.

  本发明涉及一种新型的4-(4-吡啶基)-苯甲酰胺化合物，其化学式为(I)。化合物I具有有价值的治疗性能，并且特别适用于治疗对Rho激酶（ROCKs）调节有反应的疾病。其中，R1和R2独立地是氢、羟基、氰基、C1-C8烷基、C1-C8卤代烷基、C1-C8烷氧基或C1-C8卤代烷氧基；R3、R4、R5和R6独立地是氢、羟基、卤素、氰基、C1-C8烷基、C1-C8卤代烷基、C1-C8烷氧基、C1-C8卤代烷氧基、氨基、C1-C8烷基氨基或双-(C1-C8烷基)-氨基；R7是氢、C1-C8烷基、C1-C8卤代烷基、芳基或芳基-C1-C8烷基；R8是公式-X-W的基团，其中X是单键、C1-C4-烷基或C1-C4-烷基-O-，其中在上述最后三个基团中的烷基团可以是直链或支链，并且可以部分或完全卤代和/或可以被氢氧基取代和/或可以被氧原子中断；W是选择自苯基和一个5-或6-成员的饱和、部分不饱和或芳香杂环环，其中环成员包括1、2或3个选择自O、S和N的杂原子，并且可以选择1或2个羰基基团；R9是公式-Y-Z的基团，其中Z是氢、卤素、OR11、NR12R13、S(O)m-R14、苯基（可以携带1、2、3或4个取代基R15）或一个5-或6-成员的饱和、部分不饱和或芳香杂环环；Y是线性或支链的C1-C4烷基，可以部分或完全卤代和/或可以被氢氧基和/或苯环取代；或者，如果Z是苯基或上述定义的5-或6-成员杂环环，则Y也可以是单键。
• US8445686B2
  申请人：——

  公开号：US8445686B2

  公开（公告）日：2013-05-21
• US8895749B2
  申请人：——

  公开号：US8895749B2

  公开（公告）日：2014-11-25